0
A principios de 2026, el Comité de Biotecnología de la Sociedad Brasileña de Reumatología publicó un posicionamiento sobre «la intercambiabilidad entre los medicamentos biológicos originales y...
More >- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- EC approves golimumab biosimilar Gotenfia and ranibizumab biosimilar Ranluspec
- EMA recommends approval for teriparatide biosimilar Zandoriah
- FDA approves third interchangeable ranibizumab biosimilar Nufymco
- FDA approves Poherdy (first interchangeable pertuzumab) and Armlupeg (pegfilgrastim) biosimilars
Investigación
- OECD study finds no direct link between advertising rules and biosimilar uptake
- Alcanzar los objetivos ASG en el desarrollo farmacéutico
- What is the future for the US biosimilar interchangeability designation
- Estudios de eficacia clínica en biosimilares: ¿siguen siendo necesarios?
General
- La SBR publica un posicionamiento sobre la intercambiabilidad segura entre biológicos originales y biosimilares
- Biosimilars approved in the US
- Samsung Bioepis wins Pyzchiva case; Regeneron patent rulings threaten foreign biosimilars
- Biosimilars approved in Europe
- MORE EDITORIAL SECTIONS
- Search
